RET and neoplasm: The results identified a RET A641R mutation (variant allele frequency [VAF], 28.3%), an H3-3B R9C mutation (VAF, 39.3%), and an XPO5 R519Q mutation (VAF, 25.6%) (estimated tumor cell content, 70.0%) (Table 1).